Minoxidil-induced hypertrichosis in a child with alopecia areata

Kumar, Ajay

doi:10.4103/2229-5178.202269

Cited by 6 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Minoxidil has dual uses both as an antihypertensive vasodilator medication and over‐the‐counter drug for the treatment of androgenetic alopecia (FDA approved) and alopecia areata. Systemic absorption of the drug is minimal with topical therapy, with less than 2% of the applied dose being absorbed . In our case, the excessive use (both in concentration and daily application) in combination with the patient's large surface area to body weight favored its systemic adsorption.…”

mentioning

confidence: 67%

Minoxidil‐induced hypertrichosis in an 8‐month‐old infant

2019

View full text Add to dashboard Cite

mentioning

confidence: 67%

Minoxidil‐induced hypertrichosis in an 8‐month‐old infant

2019

View full text Add to dashboard Cite

“…41,83 Side effects of minoxidil included extensive hypertrichosis. [37][38][39][40]42 Although excessive topical administration may lead to systemic absorption (manifesting as palpitations, hypotension, etc. ), the typical twice daily dose is generally safe.…”

Section: Resultsmentioning

confidence: 99%

Treatment of pediatric alopecia areata: A systematic review

Barton

Toussi

Awasthi

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background: Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with slightly greater prevalence in children than adults. Various treatment modalities exist; however, their evidence in pediatric AA patients is lacking.Objective: To evaluate the evidence of current treatment modalities for pediatric AA. Methods:We conducted a systematic review on the PubMed database in October 2019 for all published articles involving patients \18 years old. Articles discussing AA treatment in pediatric patients were included, as were articles discussing both pediatric and adult patients, if data on individual pediatric patients were available.Results: Inclusion criteria were met by 122 total reports discussing 1032 patients. Reports consisted of 2 randomized controlled trials, 4 prospective comparative cohorts, 83 case series, 2 case-control studies, and 31 case reports. Included articles assessed the use of aloe, apremilast, anthralin, anti-interferon gamma antibodies, botulinum toxin, corticosteroids, contact immunotherapies, cryotherapy, hydroxychloroquine, hypnotherapy, imiquimod, Janus kinase inhibitors, laser and light therapy, methotrexate, minoxidil, phototherapy, psychotherapy, prostaglandin analogs, sulfasalazine, topical calcineurin inhibitors, topical nitrogen mustard, and ustekinumab.Limitations: English-only articles with full texts were used. Manuscripts with adult and pediatric data were only incorporated if individual-level data for pediatric patients were provided. No meta-analysis was performed. Conclusion:Topical corticosteroids are the preferred first-line treatment for pediatric AA, as they hold the highest level of evidence, followed by contact immunotherapy. More clinical trials and comparative studies are needed to further guide management of pediatric AA and to promote the potential use of pre-existing, low-cost, and novel therapies, including Janus kinase inhibitors.

show abstract

“…A total of 10 related articles, including four systematic reviews, were found in the literature covering topical minoxidil use in pediatric AA patients 19 30 37 43 44 45 46 47 48 49 . Most of these were case reports or series, wherein minoxidil was applied once or twice a day with varying concentrations (1%~5%), and the patient age ranged between 2~14 years 43 44 45 46 47 48 . One study revealed that topical minoxidil monotherapy was more effective compared to placebo 50 .…”

Section: Resultsmentioning

confidence: 99%

Guidelines for the Management of Patients with Alopecia Areata in Korea: Part I Topical and Device-based Treatment

et al. 2023

View full text Add to dashboard Cite

Background Alopecia areata (AA) is a chronic disease with an unpredictable disease course and severe psychological impact. Objective To provide evidence- and consensus-based insights regarding the treatment of patients with AA in Korea. Methods We searched for relevant studies on the topical and device-based treatment of AA in the literature from inception until May 2021. Evidence-based recommendations were also prepared. The evidence for each statement was graded and classified according to the strength of the recommendations. Hair experts from the Korean Hair Research Society (KHRS) voted on the statements, and an agreement of 75% or greater was considered as consensus. Results Currently, there remains a scarcity of topical treatments, which is supported by robust evidence from a number of high-quality randomized controlled trials. Current evidence supports the efficacy of topical corticosteroids, corticosteroid intralesional injection, and contact immunotherapy in AA patients. Topical corticosteroids and contact immunotherapy are recommended for pediatric AA. A consensus was achieved in 6 out of 14 (42.8%), and 1 out of 5 (20.0%) statements pertaining to topical and device-based treatments in AA, respectively. The expert consensus was from a single country, and the study may not cover all the treatments used. Conclusion The present study provides up-to-date, evidence-based treatment guidelines for AA based on the consensus reached among experts after considering regional healthcare circumstances, adding diversity to the previous guidelines.

show abstract

Minoxidil-induced hypertrichosis in a child with alopecia areata

Cited by 6 publications

References 6 publications

Minoxidil‐induced hypertrichosis in an 8‐month‐old infant

Minoxidil‐induced hypertrichosis in an 8‐month‐old infant

Treatment of pediatric alopecia areata: A systematic review

Guidelines for the Management of Patients with Alopecia Areata in Korea: Part I Topical and Device-based Treatment

Contact Info

Product

Resources

About